To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.
Patients must have histologically or cytologically confirmed non-small cell lung cancer.
Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.
ECOG PS 0-2
Adequate organ and bone marrow function.
History of previous radiotherapy.
The previous immune-related pneumonitis ≥ grade 2.
Local lesions require surgery.
History of another primary malignancy.
Single group
sodium glycididazole
DrugSodium glycididazole is intravenously infused at a dose of 800mg at 60 min before radiotherapy and used on Mondays, Wednesdays and Fridays during radiotherapy.
Incidence and severity of grade 3 and above radiation esophagitis
Radiation esophagitis of grade 3 or higher is graded according to the toxicity criteria of the CTCAE v5.0.
Incidence and severity of grade 2 and above radiation pneumonitis
Radiation pneumonitis of grade 2 or higher is graded according to the toxicity criteria of the CTCAE v5.0.
Click on the lead sponsor to view all of their trials.
